Medtronic concludes enrollment in 'extreme risk' study of CoreValve

Medtronic ($MDT) has wrapped up patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The study is enrolling more than 1,500 patients in 45 sites, with approximately two-thirds of patients in the high-risk study. The system is designed to replace diseased aortic valves without open-heart surgery. Medtronic release

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.